KRAS and adenocarcinoma: Frequent decrease of FSTL1 expression in adenocarcinoma with KRAS mutation or ALK fusion and in smokers implies that FSTL1 has a critical role and may be a potential therapeutic target for some specific molecular types of lung adenocarcinoma.